NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis $1.90 -0.02 (-0.78%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sera Prognostics Stock (NASDAQ:SERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sera Prognostics alerts:Sign Up Key Stats Today's Range$1.87▼$1.9350-Day Range$1.79▼$2.3552-Week Range$1.37▼$4.09Volume2,809 shsAverage Volume51,582 shsMarket Capitalization$74.56 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Sera Prognostics, Inc. is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery. Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations. Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.AI Generated. May Contain Errors. Read More Sera Prognostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreSERA MarketRank™: Sera Prognostics scored higher than 46% of companies evaluated by MarketBeat, and ranked 551st out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSera Prognostics has a consensus price target of $5.00, representing about 160.4% upside from its current price of $1.92.Amount of Analyst CoverageSera Prognostics has only been the subject of 1 research reports in the past 90 days.Read more about Sera Prognostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Sera Prognostics are expected to decrease in the coming year, from ($0.66) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.03% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 10.66, which indicates bearish sentiment.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 8.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.51 News SentimentSera Prognostics has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sera Prognostics this week, compared to 2 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $103,854.00 in company stock.Percentage Held by Insiders11.30% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SERA Stock News HeadlinesSera Prognostics, Inc. (SERA) Q1 2026 Earnings Call TranscriptMay 7 at 3:03 AM | seekingalpha.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSMay 6 at 4:05 PM | prnewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 8 at 1:00 AM | InvestorPlace (Ad)SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026April 22, 2026 | prnewswire.comSera Prognostics Inc.April 11, 2026 | barrons.comSera Prognostics, Inc. (NASDAQ:SERA) Q4 2025 earnings call transcriptMarch 20, 2026 | msn.comSera Prognostics Earnings Call: Data-Rich, Revenue-LightMarch 19, 2026 | tipranks.comSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial ResultsMarch 19, 2026 | finanznachrichten.deSee More Headlines SERA Stock Analysis - Frequently Asked Questions How have SERA shares performed this year? Sera Prognostics' stock was trading at $2.95 at the beginning of 2026. Since then, SERA shares have decreased by 35.4% and is now trading at $1.9050. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) issued its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The firm earned $0.01 million during the quarter, compared to analysts' expectations of $0.07 million. Sera Prognostics had a negative trailing twelve-month return on equity of 39.22% and a negative net margin of 56,385.97%. Read the conference call transcript. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering on Wednesday, July 14th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Sera Prognostics' top institutional shareholders include Bank of New York Mellon Corp (0.16%). Insiders that own company stock include Zhenya Lindgardt, Austin Aerts, Paul Kearney, John J Boniface, Robert Gardner Harrison, Mansoor Raza Mirza and Joshua Phillips. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sera Prognostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings5/06/2026Today5/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:SERA CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees120Year Founded2008Price Target and Rating Average Price Target for Sera Prognostics$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+161.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.93 million Net Margins-56,385.97% Pretax Margin-39,417.28% Return on Equity-39.22% Return on Assets-29.95% Debt Debt-to-Equity RatioN/A Current Ratio1.69 Quick Ratio1.69 Sales & Book Value Annual Sales$80 thousand Price / Sales936.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.99Miscellaneous Outstanding Shares39,140,000Free Float34,721,000Market Cap$74.95 million OptionableOptionable Beta0.92 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SERA) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
